Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems (Q28218351)

Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation

Europe PubMed Central

title

Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems (English)

0 references

author name string

Hisanori Horiuchi

series ordinal

1

0 references

language of work or name

English

0 references

publication date

2006

0 references

published in

Annals of Medicine

0 references

volume

38

0 references

issue

3

0 references

page(s)

162-72

0 references

cites work

1 reference

https://api.crossref.org/works/10.1080/07853890600640657

Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance

20 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600640657

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

20 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600640657

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

20 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600640657

Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery

20 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600640657

Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?

20 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600640657

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

20 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600640657

Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs

20 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600640657

Central role of the P2Y12 receptor in platelet activation

20 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600640657

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

20 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600640657

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

20 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600640657

Coronary Plaque Disruption

20 April 2017

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

New insights into the pathogenesis and prevention of acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Atherothrombosis and high-risk plaque: part I: evolving concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Thrombin signalling and protease-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Aspirin as an antiplatelet drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Scientific and therapeutic advances in antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Aspirin non-responder status in patients with recurrent cerebral ischemic attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Aspirin resistance in stroke: 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of eryt

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Effect of ibuprofen on cardioprotective effect of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Cigarette Smoking Acutely Increases Platelet Thrombus Formation in Patients With Coronary Artery Disease Taking Aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Platelet purinergic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Functional significance of adenosine 5'-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Thrombotic thrombocytopenic purpura: the systemic clumping "plague".

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Recirculation of prostacyclin (PGI2) in the dog

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Monitoring of clopidogrel action: comparison of methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Sarpogrelate: cardiovascular and renal clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Integrin alphaIIbbeta3 and its antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Aspirin resistance:a new independent predictor of vascular events?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do no necessarily represent the views of JACCor the American College of

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Agonist selectivity and second messenger concentration in Ca2+-mediated secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Comparative Effectiveness of Adenosine Analogues as Inhibitors of Blood-Platelet Aggregation and as Vasodilators in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Assessment of platelet function assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Aspirin resistance and genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Dipyridamole potentiates the anti-aggregating effect of endothelium-derived relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657

Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600640657